Study finds British Columbia's drug decriminalization did not lower overdose deaths
A new analysis shows that British Columbia's pilot to decriminalize several hard drugs had no measurable impact on drug-related hospitalizations or toxic deaths compared with other Canadian provinces.
A recent study published in the Canadian Medical Association Journal examined British Columbia's three-year pilot that allowed adults to possess up to 2.5 grams of heroin, fentanyl, crack, cocaine, methamphetamine and MDMA without arrest. While police encounters for possession dropped sharply during the program, the province saw no significant divergence from national patterns in opioid-related hospitalizations or drug toxicity deaths.
Overdose fatalities declined 19% in B.C., yet Ontario experienced a 25% reduction over the same period. The authors argue that the lack of accompanying health interventions likely muted any potential benefits. The policy was partially rolled back in May 2024, re-criminalizing possession in public spaces, and the exemption expired on Jan. 31, 2026. Officials caution that over-promising health outcomes can erode public trust.
Why it matters
The findings question the effectiveness of drug decriminalization as a standalone solution to the overdose crisis.
In this story
